论文部分内容阅读
目的:通过观察香砂六君子丸对脾虚痰浊证大鼠小肠c AMP/PKA信号通路的影响,探讨香砂六君子丸治疗脾虚痰浊证大鼠可能机制。方法:24只SD大鼠,随机分为空白对照组、脾虚痰浊组、香砂六君子丸治疗组(以下简称治疗组),每组8只。采用高脂饲料喂养大鼠复制脾虚痰浊证动物模型,14 d后,治疗组采用香砂六君子丸灌胃治疗,空白对照组和脾虚痰浊模型组予等量生理盐水灌胃。灌胃60 d后采用ELISA法检测血浆中c AMP浓度,RT-PCR和Western blot检测大鼠小肠GP、PHK和PKA mRNA和蛋白表达水平。结果:与空白对照组相比,脾虚痰浊组小肠c AMP活性显著降低,与脾虚痰浊组相比,治疗组小肠c AMP活性显著升高;与空白对照组相比,脾虚痰浊组GP、PHK、PKA mRNA和蛋白含量显著下降,与脾虚痰浊组相比,治疗组GP、PHK、PKA mRNA和蛋白含量显著上升。结论:香砂六君子丸可能通过调控c AMP/PKA信号通路影响脾虚痰浊证大鼠。
Objective: To observe the effect of Xiangsha Liujunzi Pill on c AMP / PKA signaling pathway in small intestine of rats with phlegm-dampness syndrome of spleen deficiency syndrome and to explore the possible mechanism of Xiangsha Liujunzi Pill in treating phlegm-turbidity syndrome of the spleen deficiency syndrome. Methods: Twenty-four SD rats were randomly divided into blank control group, Spleen deficiency and phlegm turbidity group, Xiangsha Liujunzi pill treatment group (hereinafter referred to as treatment group), with 8 rats in each group. The animals were fed with high-fat diet to establish the animal model of phlegm-dampness syndrome of spleen deficiency. After 14 days, the treatment group was treated with Xiangsha Liujunzi pill. The blank control group and the spleen-phlegm-turbidity model group were given normal saline. The concentrations of cAMP in plasma were detected by ELISA 60 days after gavage. The mRNA and protein expressions of GP, PHK and PKA in small intestine were detected by RT-PCR and Western blot. Results: Compared with the blank control group, the activity of cAMP in the small intestine of spleen deficiency and phlegm turbidity group was significantly lower than that in the spleen deficiency and phlegm turbidity group, and the activity of c AMP in the small intestine of the treatment group was significantly increased. Compared with the blank control group, , PHK, PKA mRNA and protein content decreased significantly, compared with the spleen deficiency phlegm group, the treatment group GP, PHK, PKA mRNA and protein levels increased significantly. Conclusion: Xiangsha Liujunzi Pill may affect phlegm-turbidity syndrome rats by regulating c AMP / PKA signaling pathway.